Patents Assigned to Signal Pharmaceuticals
  • PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY
    Publication number: 20130289271
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: June 26, 2013
    Publication date: October 31, 2013
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Weiming Xu, Loui Madakamutil, Kimberly Elizabeth Fultz, Rama Narla, Sabita Sankar, Jan Elsner
  • Methods of synthesis and purification of heteroaryl compounds
    Patent number: 8569494
    Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: October 29, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Gingsee Lee, Garrick Packard, Jingjing Zhao, Patrick Anthony Jokiel, Deborah Mortensen, Jennifer Riggs, Juan Antonio Gamboa, Marie Georges Beauchamps, Matthew Michael Kreilein, Mohit Atul Kothare, Sophie Perrin-Ninkovic, Philip James Pye, William Wei-Hwa Leong, Jan Elsner, Anusuya Choudhury
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20130245028
    Abstract: Provided herein are methods for treating or preventing ETS overexpressing castration-resistant prostate cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having ETS overexpressing castration-resistant prostate cancer.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 19, 2013
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Heather Raymon, Toshiya Tsuji, Lisa Sapinoso
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20130245027
    Abstract: Provided herein are methods for treating or preventing triple negative breast cancer or hormone receptor positive breast cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having triple negative breast cancer or hormone receptor positive breast cancer.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 19, 2013
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Heather Raymon, Rama K. Narla
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20130245029
    Abstract: Provided herein are methods for treating or preventing ETS overexpressing Ewings sarcoma, comprising administering an effective amount of a TOR kinase inhibitor to a patient having ETS overexpressing Ewings sarcoma.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 19, 2013
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20130245026
    Abstract: Provided herein are methods for treating or preventing head and neck squamous cell carcinoma, comprising administering an effective amount of a TOR kinase inhibitor to a patient having head and neck squamous cell carcinoma.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 19, 2013
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Heather Raymon, Lilly Loraine Wong
  • METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS
    Publication number: 20130245254
    Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.
    Type: Application
    Filed: April 30, 2013
    Publication date: September 19, 2013
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Gingsee Lee, Garrick Packard, Jingjing Zhao, Patrick Anthony Jokiel, Deborah Mortensen, Jennifer Riggs, Juan Antonio Gamboa, Marie Georges Beauchamps, Matthew Michael Kreilein, Mohit Atul Kothare, Sophie Perrin-Ninkovic, Philip Pye, William Wei-Hwa Leong, Jan Elsner, Anusuya Choudhury
  • HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH
    Publication number: 20130225564
    Abstract: Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.
    Type: Application
    Filed: March 18, 2013
    Publication date: August 29, 2013
    Applicant: Signal Pharmaceuticals, LLC
    Inventor: Signal Pharmaceuticals, LLC
  • METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
    Publication number: 20130225518
    Abstract: Provided herein are methods for treating or preventing advanced non-small cell lung cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of erlotinib or a cytidine analog to a patient having advanced non-small cell lung cancer.
    Type: Application
    Filed: February 22, 2013
    Publication date: August 29, 2013
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventor: Signal Pharmaceuticals, LLC
  • Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway
    Patent number: 8507492
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: August 13, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Weiming Xu, Loui Madakamutil, Kimberly Fultz, Rama K. Narla, Sabita Sankar, Jan Elsner
  • Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
    Patent number: 8492381
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: July 23, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Weiming Xu, Loui Madakamutil, Kimberly Fultz, Rama K. Narla, Sabita Sankar, Jan Elsner
  • IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS
    Publication number: 20130158023
    Abstract: Provided herein are methods for predicting the LKB1 status of a patient or a biological sample, comprising the measurement of particular gene expression levels relative to a set of reference levels that represent the gene expression level of a biological wild-type sample without LKB1 gene or protein loss or mutation and the gene expression level of a reference sample with LKB1 gene or protein loss or mutation. Further provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by particular gene expression levels.
    Type: Application
    Filed: August 2, 2012
    Publication date: June 20, 2013
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Yuhong L. Ning, Weiming Xu, Rajesh Chopra, Peter Worland, Shuichan Xu
  • PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE
    Publication number: 20130142873
    Abstract: Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologues and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition.
    Type: Application
    Filed: November 30, 2012
    Publication date: June 6, 2013
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventor: Signal Pharmaceuticals, LLC
  • Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines
    Patent number: 8440661
    Abstract: Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: May 14, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Brydon L. Bennett, Kate Northcote, Brian Edwin Cathers
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20130102613
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Application
    Filed: October 18, 2012
    Publication date: April 25, 2013
    Applicant: Signal Pharmaceuticals, LLC
    Inventor: Signal Pharmaceuticals, LLC
  • Methods of treatment using heteroaryl compounds and compositions thereof
    Patent number: 8383634
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1, R3, R4, L, X, Y, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: February 26, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Deborah Sue Mortensen, Maria Mercedes Delgado Mederos, John Joseph Sapienza, Ronald J. Albers, Steven Spencer Clareen, Kimberly Lyn Schwarz, Jason Simon Parnes, Jennifer R. Riggs, Patrick William Papa, Sayee Gajanan Hegde, Jeffrey Mark McKenna
  • Methods of treatment comprising the administration of heteroaryl compounds
    Patent number: 8372976
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: February 12, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Deborah Sue Mortensen, Maria Mercedes Delgado Mederos, John Joseph Sapienza, Ronald J. Albers, Branden G. Lee, Roy Leonard Harris, III, Graziella Isabel Shevlin, Dehua Huang, Kimberly Lyn Schwarz, Garrick K. Packard, Jason Simon Parnes, Patrick William Papa, Lida Radnia Tehrani, Sophie Perrin-Ninkovic, Jennifer R. Riggs
  • Aminotriazolopyridines, compositions thereof, and methods of treatment therewith
    Patent number: 8299056
    Abstract: Provided herein are Heteroaryl Compounds of formula (I): wherein R1 and R2 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing inflammatory conditions or cancer, and conditions treatable or preventable by inhibition of a kinase or a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a subject in need thereof.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: October 30, 2012
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sogole Bahmanyar, R.J. Bates, Kate Blease, Andrew Calabrese, Thomas Daniel, Mercedes Delgado, Jan Elsner, Paul Erdman, Bruce Fahr, Gregory Ferguson, Branden Lee, Lisa Nadolny, Garrick Packard, Patrick Papa, Veronique Plantevin-Krenitsky, Jennifer Riggs, Patricia Rohane, Sabita Sankar, John Sapienza, Yoshitaka Satoh, Victor Sloan, Randall Stevens, Lida Tehrani, Jayashree Tikhe, Eduardo Torres, Andrew Wallace, Brandon Wade Whitefield, Jingjing Zhao
  • Compounds and methods for modulating activation of NF-?B
    Patent number: 8263326
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: September 11, 2012
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith
    Patent number: 8158635
    Abstract: Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-cyclohexan-1-ol, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: April 17, 2012
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Marie G. Beauchamps, Louise Michelle Cameron, Robert Hilgraf, Mohit Atul Kothare, Manohar T. Saindane, Jean Xu